Skip to main content
. 2023 Jun 17;10(24):2301505. doi: 10.1002/advs.202301505

Figure 5.

Figure 5

TGF‐β mediates myoCAF transition in Bmal1−/− tumors. A) Immunoblot analysis of p‐SMAD2, t‐SMAD2, α‐SMA, FAP, and PDGFRβ of vehicle‐ and SB‐431542‐treated tumors grown in Bmal1+/+ and Bmal1−/− mice. B) Quantification of protein levels of p‐SMAD2, α‐SMA, FAP, and PDGFRβ in Bmal1+/+ and Bmal1−/− mice (n = 4 samples per group). C) ELISA quantification of protein levels of active TGF‐β in vehicle‐ and SB‐431542‐treated tumors and plasma of tumor‐bearing mice (n = 4 samples per group). D) Cell motility and quantification of FACS‐isolated FAP+ CAFs from vehicle‐ and SB‐431542‐treated Bmal1+/+ and Bmal1−/− tumors (n = 5 colonies per group). Quantification of CAF number after 48 h (n = 5 random fields per group). Data presented as mean ± S.E.M. ***P < 0.001, ns = not significant; one‐way ANOVA.